Physician profile
John T Cobb
NPI 1164429627
$4,919.27
in general payments reported to CMS, 2019-2025
22 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $705 · 2021: $885 · 2022: $715 · 2023: $950 · 2024: $801 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,713.87 | 2019-2024 | Clareon, Ngenuity |
| Johnson & Johnson Surgical Vision, INC. | $644.83 | 2019-2023 | Tecnis Simplicity, Tecnis Iol |
| Coopervision INC. | $500.00 | 2021-2022 | |
| Abbvie INC. | $304.35 | 2022-2025 | |
| Carl Zeiss Meditec, INC. | $208.03 | 2019-2020 | |
| Amgen INC. | $195.95 | 2024-2025 | Tepezza |
| Allergan, INC. | $195.45 | 2020-2022 | |
| Rxsight INC | $144.44 | 2024 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Eyepoint US, INC. | $127.79 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.52 | 2019 | |
| Horizon Therapeutics Plc | $121.23 | 2023 | Tepezza |
| Apellis Pharmaceuticals, INC. | $119.02 | 2023 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $110.28 | 2021 | |
| Astellas Pharma US INC | $104.63 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $67.72 | 2020-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $67.61 | 2023-2024 | Vyzulta, Xipere, Miebo |
| Harrow Eye, LLC | $60.86 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $40.98 | 2022 | |
| Aerie Pharmaceuticals, INC. | $22.06 | 2019 | |
| Sight Sciences, INC. | $18.78 | 2019 | |
| Glaukos Corporation | $15.28 | 2023 | |
| Sun Pharmaceutical Industries INC. | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.